108 related articles for article (PubMed ID: 32382773)
1. Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States.
Verstovsek S; Yu J; Kish JK; Paranagama D; Kaufman J; Myerscough C; Grunwald MR; Colucci P; Mesa R
Ann Hematol; 2020 Nov; 99(11):2555-2564. PubMed ID: 32382773
[TBL] [Abstract][Full Text] [Related]
2. Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review.
Mitra D; Kaye JA; Piecoro LT; Brown J; Reith K; Mughal TI; Sarlis NJ
Cancer Med; 2013 Dec; 2(6):889-98. PubMed ID: 24403262
[TBL] [Abstract][Full Text] [Related]
3. Prognostic risk models for transplant decision-making in myelofibrosis.
Hernández-Boluda JC; Pereira A; Correa JG; Alvarez-Larrán A; Ferrer-Marín F; Raya JM; Martínez-López J; Velez P; Pérez-Encinas M; Estrada N; García-Gutiérrez V; Fox ML; Payer A; Kerguelen A; Cuevas B; Durán MA; Ramírez MJ; Gómez-Casares MT; Mata-Vázquez MI; Mora E; Gómez M; Cervantes F
Ann Hematol; 2018 May; 97(5):813-820. PubMed ID: 29396714
[TBL] [Abstract][Full Text] [Related]
4. Disease and Clinical Characteristics of Patients With a Clinical Diagnosis of Myelofibrosis Enrolled in the MOST Study.
Gerds AT; Lyons RM; Colucci P; Kalafut P; Paranagama D; Verstovsek S
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):e532-e540. PubMed ID: 35256316
[TBL] [Abstract][Full Text] [Related]
5. Differences in treatment goals and perception of symptom burden between patients with myeloproliferative neoplasms (MPNs) and hematologists/oncologists in the United States: Findings from the MPN Landmark survey.
Mesa RA; Miller CB; Thyne M; Mangan J; Goldberger S; Fazal S; Ma X; Wilson W; Paranagama DC; Dubinski DG; Naim A; Parasuraman S; Boyle J; Mascarenhas JO
Cancer; 2017 Feb; 123(3):449-458. PubMed ID: 27690182
[TBL] [Abstract][Full Text] [Related]
6. Myelofibrosis: best practices, controversies and 2019 update.
Cruz NM; Gergis U; Silver RT
Expert Rev Hematol; 2020 Jan; 13(1):71-84. PubMed ID: 31709843
[No Abstract] [Full Text] [Related]
7. Prevalence and Effect on Survival of Pulmonary Hypertension in Myelofibrosis.
Austin M; Quesenberry PJ; Ventetuolo CE; Liang O; Reagan JL
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):593-597. PubMed ID: 31262666
[TBL] [Abstract][Full Text] [Related]
8. Primary myelofibrosis: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2011 Dec; 86(12):1017-26. PubMed ID: 22086865
[TBL] [Abstract][Full Text] [Related]
9. What is pre-fibrotic myelofibrosis and how should it be managed in 2018?
Curto-Garcia N; Ianotto JC; Harrison CN
Br J Haematol; 2018 Oct; 183(1):23-34. PubMed ID: 30328618
[TBL] [Abstract][Full Text] [Related]
10. Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2016 Dec; 91(12):1262-1271. PubMed ID: 27870387
[TBL] [Abstract][Full Text] [Related]
11. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
[TBL] [Abstract][Full Text] [Related]
12. Clinical Correlates and Prognostic Significance of IL-8, sIL-2R, and Immunoglobulin-Free Light Chain Levels in Patients with Myelofibrosis.
Barabanshikova MV; Dubina IA; Lapin SV; Morozova EV; Vlasova JJ; Ivanova MO; Moiseev IS; Afanasyev BV
Oncol Res Treat; 2017; 40(10):574-578. PubMed ID: 28946149
[TBL] [Abstract][Full Text] [Related]
13. Medical complications, resource utilization and costs in patients with myelofibrosis by frequency of blood transfusion and iron chelation therapy.
Vekeman F; Cheng WY; Sasane M; Huynh L; Duh MS; Paley C; Mesa RA
Leuk Lymphoma; 2015; 56(10):2803-11. PubMed ID: 25676036
[TBL] [Abstract][Full Text] [Related]
14. Primary myelofibrosis: 2019 update on diagnosis, risk-stratification and management.
Tefferi A
Am J Hematol; 2018 Dec; 93(12):1551-1560. PubMed ID: 30039550
[TBL] [Abstract][Full Text] [Related]
15. Primary myelofibrosis: 2013 update on diagnosis, risk-stratification, and management.
Tefferi A
Am J Hematol; 2013 Feb; 88(2):141-50. PubMed ID: 23349007
[TBL] [Abstract][Full Text] [Related]
16. Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.
Boddu P; Masarova L; Verstovsek S; Strati P; Kantarjian H; Cortes J; Estrov Z; Pierce S; Pemmaraju N
Ann Hematol; 2018 Jan; 97(1):109-121. PubMed ID: 29143068
[TBL] [Abstract][Full Text] [Related]
17. Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Moulard O; Mehta J; Fryzek J; Olivares R; Iqbal U; Mesa RA
Eur J Haematol; 2014 Apr; 92(4):289-97. PubMed ID: 24372927
[TBL] [Abstract][Full Text] [Related]
18. Dynamic of bone marrow fibrosis regression predicts survival after allogeneic stem cell transplantation for myelofibrosis.
Kröger N; Zabelina T; Alchalby H; Stübig T; Wolschke C; Ayuk F; von Hünerbein N; Kvasnicka HM; Thiele J; Kreipe HH; Büsche G
Biol Blood Marrow Transplant; 2014 Jun; 20(6):812-5. PubMed ID: 24589549
[TBL] [Abstract][Full Text] [Related]
19. Transfusion-dependency at presentation and its acquisition in the first year of diagnosis are both equally detrimental for survival in primary myelofibrosis--prognostic relevance is independent of IPSS or karyotype.
Tefferi A; Siragusa S; Hussein K; Schwager SM; Hanson CA; Pardanani A; Cervantes F; Passamonti F
Am J Hematol; 2010 Jan; 85(1):14-7. PubMed ID: 20029953
[TBL] [Abstract][Full Text] [Related]
20. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
